GGrantIndex
← Leaderboards

Enid R Neptune

Johns Hopkins University

$11,248,461
Attributed
$12,898,126
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY200524
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$12,898,126 · 8

By mechanism

R01$11,100,768 · 5
P50$976,508 · 1
K08$656,850 · 1
R03$164,000 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Chronic

Research focus

ChronicCigarette SmokeLungLung DiseasesEpithelial CellsLung InjuryPulmonary EmphysemaReceptorApoptosisSignal TransductionChronic Obstructive Airway DiseaseMediatingAttenuatedInflammatoryInjuryCellsAlveolarGeneticCohortCause Of DeathAllelesCigarette Smoke-InducedAdultComplex

Grant awards (31)

Hepatocyte Growth Factor Signaling and Airspace Maintenance$738,663
R01 · FY2024 · HL · contact PI
Hepatocyte Growth Factor Signaling and Airspace Maintenance$755,014
R01 · FY2023 · HL · contact PI
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair$612,340
R01 · FY2023 · HL · contact PI
Hepatocyte Growth Factor Signaling and Airspace Maintenance$744,171
R01 · FY2022 · HL · contact PI
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair$693,753
R01 · FY2022 · HL · contact PI
Hepatocyte Growth Factor Signaling and Airspace Maintenance$759,790
R01 · FY2021 · HL · contact PI
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair$613,110
R01 · FY2021 · HL · contact PI
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair$622,479
R01 · FY2020 · HL · contact PI
New Inhalation Therapy for COPD$409,375
R01 · FY2020 · HL
New Inhalation Therapy for COPD$409,375
R01 · FY2019 · HL
New Inhalation Therapy for COPD$409,323
R01 · FY2018 · HL
Mucus Microstructure and Osmotic Pressure: Biomarkers for CB in COPD$399,855
R01 · FY2018 · HL · contact PI
New Inhalation Therapy for COPD$408,646
R01 · FY2017 · HL
Mucus Microstructure and Osmotic Pressure: Biomarkers for CB in COPD$399,855
R01 · FY2017 · HL · contact PI
Mucus Microstructure and Osmotic Pressure: Biomarkers for CB in COPD$413,485
R01 · FY2016 · HL · contact PI
Mucus Microstructure and Osmotic Pressure: Biomarkers for CB in COPD$449,417
R01 · FY2015 · HL · contact PI
TGFb Modulation: Therapeutic Targeting for COPD-Emphysema$484,510
P50 · FY2012 · HL · contact PI
TGFb Modulation: Therapeutic Targeting for COPD-Emphysema$491,998
P50 · FY2011 · HL · contact PI
The Role of Hepatocyte Growth Factor Signaling Airspace Homeostasis$410,000
R01 · FY2011 · HL · contact PI
The Role of Hepatocyte Growth Factor Signaling Airspace Homeostasis$410,000
R01 · FY2010 · HL · contact PI
The Role of Hepatocyte Growth Factor Signaling Airspace Homeostasis$410,000
R01 · FY2009 · HL · contact PI
The Role of Hepatocyte Growth Factor Signaling Airspace Homeostasis$221,717
R01 · FY2009 · HL · contact PI
Tissue-based validation of COPD Genetic Studies using Lung Health Study Cohort$82,000
R03 · FY2009 · HL · contact PI
The Role of Hepatocyte Growth Factor Signaling Airspace Homeostasis$410,000
R01 · FY2008 · HL · contact PI
Tissue-based validation of COPD Genetic Studies using Lung Health Study Cohort$82,000
R03 · FY2008 · HL · contact PI
The Role of Hepatocyte Growth Factor Signaling Airspace Homeostasis$400,400
R01 · FY2007 · HL · contact PI
Alveolization in Fibrillin-1 Defective Mice$131,490
K08 · FY2005 · HL
Alveolization in Fibrillin-1 Defective Mice$131,490
K08 · FY2004 · HL
Alveolization in Fibrillin-1 Defective Mice$131,490
K08 · FY2003 · HL
Alveolization in Fibrillin-1 Defective Mice$131,490
K08 · FY2002 · HL
Alveolization in Fibrillin-1 Defective Mice$130,890
K08 · FY2001 · HL